Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness

Chun-Pu Lin1, Pierre L Levy2, Astrid Alflen3

  • 1Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Cancer Cell
|March 15, 2024
PubMed

Insights

Identifying genes that regulate T cell fitness is crucial for cancer immunotherapy. This study reveals novel regulators of T cell function under different stimulation conditions, offering new therapeutic targets to enhance anti-tumor activity.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • T cells are critical for anti-tumor immunity.
  • Identifying regulators of T cell fitness is essential for developing effective cancer immunotherapies.
  • Systematic studies on genes uniquely or broadly impacting T cell fitness are lacking.

Purpose of the Study:

  • To uncover genes that regulate T cell fitness under various stimulation conditions.
  • To identify novel therapeutic targets for enhancing T cell-mediated anti-tumor activity.

Main Methods:

  • Genome-scale CRISPR-Cas9 knockout screens were performed on primary CD8 T cells.
  • Cells were subjected to three distinct stimulation modes: intense (activation-induced cell death), acute (expansion), and chronic (dysfunction).
  • Gene functions were analyzed based on their impact on T cell fitness across different stimulations.

Main Results:

  • Several novel regulators of T cell fitness were identified, in addition to known ones.
  • Dap5 ablation enhanced translation and tumor killing across all tested conditions.
  • Loss of Icam1-mediated T cell clustering boosted expansion and effector functions.
  • Ctbp1 inactivation promoted functional T cell persistence specifically under chronic stimulation.

Conclusions:

  • This study functionally annotates regulators of T cell fitness based on their specific or shared contributions to anti-tumor activity.
  • The identified genes, such as Dap5, Icam1, and Ctbp1, represent potential therapeutic targets for improving cancer immunotherapy.
  • Understanding these regulators provides insights into T cell responses to different immune challenges.